Agreements

Date: 2016-03-01

Type of information: Product acquisition

Compound: Moventig® (naloxegol)

Company: AstraZeneca (UK) Prostrakan, a subsidiary of Kyowa Hakko Kirin (Japan)

Therapeutic area: Gastrointestinal diseases - Digestive diseases

Type agreement: licensing - commercialisation

Action mechanism:

• peripherally-acting mu-opioid receptor antagonist (PAMORA) Moventig® is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
• Moventig® is part of the exclusive worldwide licence agreement announced on 21 September 2009 between AstraZeneca and Nektar Therapeutics. Moventig® was developed using Nektar’s oral small molecule polymer conjugate technology. The drug was granted Marketing Authorisation by the European Medicines Agency in December 2014.
• Moventig® is currently available in the UK, Ireland, Germany, the Nordics, Austria and Switzerland. Outside the EU, it was launched in the US in March 2015 and in Canada in October 2015 under the brand name Movantik.

Disease: opioid-induced constipation in adult patients who have had an inadequate response to laxative(s)

Details: • On March 1, 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin, for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).    

Financial terms: Under the terms of the agreement, ProStrakan will make an upfront payment to AstraZeneca of $70 million, to acquire the rights to sell and develop Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein. ProStrakan will make additional payments contingent on market access decisions in certain European markets, and will pay AstraZeneca tiered double-digit royalties on sales as well as sales milestones. In line with AstraZeneca’s ongoing interest in Moventig globally, certain strategic decisions will be made jointly between AstraZeneca and ProStrakan in the European territory. The transaction does not include the transfer of any AstraZeneca employees or facilities.

Latest news:

Is general: Yes